Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy
Status:
Completed
Trial end date:
2019-08-31
Target enrollment:
Participant gender:
Summary
Tenofovir+lamivudine+efavirenz is still the first line regimen of combination antiretroviral
therapy in developing countries. Based on our previous data, we aim to evaluate whether
reduce the dose of tenofovir and efavirenz could decreasing the incidence of the side effects
while not scarifying their virological efficacy.
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai Public Health Clinical Center
Collaborators:
The Second Hospital of Nanjing Medical University Yunnan Provincial Infectious Disease Hospital